Nivolumab versus everolimus in advanced renal-cell carcinoma
Academic Article
Overview
MeSH Major
Antibodies, Monoclonal
Antineoplastic Agents
Carcinoma, Renal Cell
Kidney Neoplasms
Sirolimus
abstract
Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).